CN100338036C - 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮 - Google Patents

对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮 Download PDF

Info

Publication number
CN100338036C
CN100338036C CNB998050296A CN99805029A CN100338036C CN 100338036 C CN100338036 C CN 100338036C CN B998050296 A CNB998050296 A CN B998050296A CN 99805029 A CN99805029 A CN 99805029A CN 100338036 C CN100338036 C CN 100338036C
Authority
CN
China
Prior art keywords
phenyl
amino
methyl
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998050296A
Other languages
English (en)
Chinese (zh)
Other versions
CN1297438A (zh
Inventor
阿明·赫克尔
雷纳·沃尔特
沃尔夫冈·格雷尔
雅各布斯·C·A·范米尔
诺伯特·雷德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1297438A publication Critical patent/CN1297438A/zh
Application granted granted Critical
Publication of CN100338036C publication Critical patent/CN100338036C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CNB998050296A 1998-04-15 1999-04-10 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮 Expired - Fee Related CN100338036C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816624.9 1998-04-15
DE19816624A DE19816624A1 (de) 1998-04-15 1998-04-15 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
CN1297438A CN1297438A (zh) 2001-05-30
CN100338036C true CN100338036C (zh) 2007-09-19

Family

ID=7864562

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998050296A Expired - Fee Related CN100338036C (zh) 1998-04-15 1999-04-10 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮

Country Status (31)

Country Link
EP (1) EP1071665B1 (enExample)
JP (1) JP4015365B2 (enExample)
KR (1) KR100588250B1 (enExample)
CN (1) CN100338036C (enExample)
AR (1) AR015763A1 (enExample)
AT (1) ATE251138T1 (enExample)
AU (1) AU749829B2 (enExample)
BG (1) BG64443B1 (enExample)
BR (1) BR9909688A (enExample)
CA (1) CA2323111C (enExample)
CO (1) CO5011040A1 (enExample)
DE (2) DE19816624A1 (enExample)
DK (1) DK1071665T3 (enExample)
EA (1) EA003532B1 (enExample)
EE (1) EE04432B1 (enExample)
ES (1) ES2207209T3 (enExample)
HU (1) HUP0101568A3 (enExample)
ID (1) ID26420A (enExample)
IL (1) IL138036A0 (enExample)
MY (1) MY122357A (enExample)
NO (1) NO317298B1 (enExample)
NZ (1) NZ507967A (enExample)
PL (1) PL343314A1 (enExample)
PT (1) PT1071665E (enExample)
SK (1) SK283824B6 (enExample)
TR (1) TR200002980T2 (enExample)
TW (1) TW510897B (enExample)
UA (1) UA63009C2 (enExample)
WO (1) WO1999052869A1 (enExample)
YU (1) YU59800A (enExample)
ZA (1) ZA200004623B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285872A (zh) * 2018-12-06 2020-06-16 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001016130A1 (de) * 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituierte indolinone als tyrosinkinase inhibitoren
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002048114A1 (en) * 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
DE60318188T2 (de) 2002-03-26 2008-12-11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
DE602004017884D1 (de) * 2003-10-03 2009-01-02 Boehringer Ingelheim Pharma Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
DE102004012070A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ES2326907T3 (es) 2004-12-27 2009-10-21 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso.
AU2006254758B2 (en) * 2005-06-10 2012-04-05 Merck Patent Gmbh Oxindoles as kinase inhibitors
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
BRPI0720131A2 (pt) 2006-12-06 2014-02-04 Boehringer Ingelheim Int Glicocorticoides miméticos, métodos para fazê-los, composições farmacêuticas e usos dos mesmos.
KR20110020902A (ko) 2008-06-06 2011-03-03 베링거 인겔하임 인터내셔날 게엠베하 글루코코르티코이드 유사체, 이의 제조방법, 약제학적 조성물 및 이의 용도
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
EP2780322B1 (en) * 2011-11-14 2018-05-16 Ligand Pharmaceuticals, Inc. Methods and compositions associated with the granulocyte colony-stimulating factor receptor
WO2014150252A1 (en) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN107033064B (zh) * 2017-04-28 2019-07-09 西安医学院 一种3-(吗啉取代芳亚胺基)吲哚类化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022976A1 (en) * 1995-01-26 1996-08-01 Pharmacia S.P.A. Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
CN1303374A (zh) * 1998-06-04 2001-07-11 贝林格尔英格海姆法玛公司 取代的吲哚满酮,其制法及其作为药物组合物的用途
CN1391557A (zh) * 1999-10-13 2003-01-15 贝林格尔英格海姆法玛公司 6－位取代的吲哚满酮,其制备及其作为药物组合物的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022976A1 (en) * 1995-01-26 1996-08-01 Pharmacia S.P.A. Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
CN1278794A (zh) * 1997-09-05 2001-01-03 葛兰素集团有限公司 用作蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制剂的取代的2－羟基吲哚衍生物
CN1303374A (zh) * 1998-06-04 2001-07-11 贝林格尔英格海姆法玛公司 取代的吲哚满酮,其制法及其作为药物组合物的用途
CN1391557A (zh) * 1999-10-13 2003-01-15 贝林格尔英格海姆法玛公司 6－位取代的吲哚满酮,其制备及其作为药物组合物的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285872A (zh) * 2018-12-06 2020-06-16 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途
CN111285872B (zh) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 吲哚-2-酮衍生物及其制备方法与用途

Also Published As

Publication number Publication date
DE19816624A1 (de) 1999-10-21
EE200000598A (et) 2002-04-15
ID26420A (id) 2000-12-21
BG64443B1 (en) 2005-02-28
ES2207209T3 (es) 2004-05-16
ATE251138T1 (de) 2003-10-15
NO20005151L (no) 2000-10-13
CA2323111C (en) 2009-09-15
AU749829B2 (en) 2002-07-04
PT1071665E (pt) 2004-02-27
ZA200004623B (en) 2001-05-30
EP1071665A1 (de) 2001-01-31
NO20005151D0 (no) 2000-10-13
TW510897B (en) 2002-11-21
DE59907199D1 (de) 2003-11-06
DK1071665T3 (da) 2004-01-05
SK15132000A3 (sk) 2001-03-12
HUP0101568A2 (hu) 2001-09-28
BG104813A (bg) 2001-08-31
UA63009C2 (en) 2004-01-15
EP1071665B1 (de) 2003-10-01
MY122357A (en) 2006-04-29
BR9909688A (pt) 2000-12-19
AU3814999A (en) 1999-11-01
TR200002980T2 (tr) 2001-02-21
AR015763A1 (es) 2001-05-16
JP4015365B2 (ja) 2007-11-28
YU59800A (sh) 2003-04-30
PL343314A1 (en) 2001-08-13
NZ507967A (en) 2003-04-29
SK283824B6 (sk) 2004-02-03
NO317298B1 (no) 2004-10-04
EA200001021A1 (ru) 2001-06-25
JP2002511449A (ja) 2002-04-16
HUP0101568A3 (en) 2002-12-28
KR100588250B1 (ko) 2006-06-13
WO1999052869A1 (de) 1999-10-21
KR20010042731A (ko) 2001-05-25
EE04432B1 (et) 2005-02-15
CO5011040A1 (es) 2001-02-28
IL138036A0 (en) 2001-10-31
CN1297438A (zh) 2001-05-30
CA2323111A1 (en) 1999-10-21
EA003532B1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
CN100338036C (zh) 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮
CN1198613C (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1063442C (zh) 氨基噻唑衍生物、含有它们的药物组合物及其用途
CN1166645C (zh) 双环杂环化合物,含有该化合物的药物组合物,该化合物的用途及其制备方法
CN1257891C (zh) 含氮五员环化合物
CN1193025C (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1192773C (zh) 环胺ccr3拮抗剂
CN1146551C (zh) 取代的二氮杂环庚烷化合物、含有其的药物组合物及用途
CN1303374A (zh) 取代的吲哚满酮,其制法及其作为药物组合物的用途
CN1678579A (zh) 吲哚－3－硫衍生物
CN1128260A (zh) 新的哌啶化合物、其制备方法和含有它们的药用组合物
HK1043124A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
CN1260345A (zh) 酰肼化合物、其制备方法及其药物组合物
CN1079464A (zh) 治疗包括胆碱能功能降低的病症有价值的吲哚酮和吲哚二酮的衍生物的制备方法
CN1030415A (zh) 饱和的杂环碳酰胺衍生物和它的制备方法
CN1720225A (zh) 具有5－羟色胺受体亲和性的n－芳基磺酰－3－取代吲哚及其制备方法和含有其的药物组合物
CN1239952A (zh) 用作nos抑制剂的6－苯基吡啶基－2－胺衍生物
CN1649853A (zh) 噻唑烷酮类化合物、其制备方法以及作为药物的应用
CN1319090A (zh) 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
CN1361100A (zh) 新的杂环衍生物及其医药用途
CN1921848A (zh) 新型氮杂双环衍生物、其制备方法及包含其的药物组合物
CN86100964A (zh) 哌啶化合物的制备方法
CN1427825A (zh) 吲哚满－2－酮衍生物、其制备方法及其作为催产素受体配体的应用
CN1509270A (zh) 在6-位取代的吲哚满酮,其制法及其作为激酶抑制剂的用途
CN1960727A (zh) 用作组胺－3受体的配体的萘衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1035730

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070919

Termination date: 20110410